You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zucali PA, Lin C, Carthon BC, et al
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Journal for ImmunoTherapy of Cancer 2022;10:e003697. doi: 10.1136/jitc-2021-003697